ALNY:
The current live price is 328.05, reflecting a +0.82% change from the previous price.
Support and Resistance Levels
The pivot point is at 325.38, with support levels also at 325.38 and resistance levels at 325.38.
Indicators
RSI is at 54.36, indicating a neutral trend. ATR is 0.65531, suggesting lower volatility. ADX is at 25.41, indicating a weak trend. The price is above the 50-day SMA of 325.38. Parabolic SAR is at 326.03697, suggesting a possible bullish scenario.
Market Sentiment
Given the pivot point at 325.38 and supportive indicators, a bullish trend may continue.
ALNY Signals & Technical Analysis
Last Updated: <% indicators.interval.updated|date:'MMM d, y h:mm:ss a' %>
Alnylam Pharmaceuticals Inc. (Symbol: ALNY) is a pioneering biotechnology firm dedicated to transforming the treatment landscape for genetically-defined diseases. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam specializes in RNA interference (RNAi) technology, which enables the silencing of disease-causing genes at the RNA level. This innovative approach has positioned the company as a leader in developing therapies for rare and prevalent diseases associated with genetic mutations. With a commitment to scientific excellence and patient-centric solutions, Alnylam has become synonymous with groundbreaking advancements in the field of genetic medicine.
Market Position
Alnylam Pharmaceuticals holds a prominent position in the biopharmaceutical industry, particularly within the RNAi therapeutics market. With a robust pipeline of investigational and commercial products, the company has successfully launched several therapies, including ONPATTRO® (patisiran), which was the first-ever RNAi therapy approved for the treatment of hereditary transthyretin-mediated amyloidosis. This significant milestone not only underscores Alnylam's innovative capabilities but also highlights its dedication to addressing unmet medical needs. The company continues to expand its product offerings and explore new indications, reinforcing its status as a frontrunner in biotechnology.
Key Financial Highlights
Alnylam has demonstrated strong financial performance, supported by its innovative product portfolio and strategic partnerships. As of October 2023, the company reported significant revenue growth driven by the sales of its RNAi therapeutics. Alnylam's financial stability is further enhanced by collaborations with major pharmaceutical companies, which provide both funding and shared expertise. With a strong balance sheet and a growing market presence, Alnylam is well-positioned for future growth, focusing on expanding its pipeline and advancing new therapies through clinical trials. The company remains committed to exploring additional applications of its RNAi technology, thereby solidifying its leadership in the biotechnology sector.
<% (signals.list.current.rate).substr(0,7) %>
<% signal.analyst %>
